The development of COVID-19 treatment
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
Therapeutic advances in COVID-19
N Murakami, R Hayden, T Hills, H Al-Samkari… - Nature Reviews …, 2023 - nature.com
Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …
millions of lives. Unlike the early days of the pandemic, when management decisions were …
[PDF][PDF] Therapeutics and COVID-19: living guideline, 13 January 2023
World Health Organization - 2023 - apps.who.int
As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
Convalescent plasma for covid-19–induced ARDS in mechanically ventilated patients
B Misset, M Piagnerelli, E Hoste… - … England Journal of …, 2023 - Mass Medical Soc
Background Passive immunization with plasma collected from convalescent patients has
been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are …
been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are …
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled …
Although most randomized controlled trials have shown negative results, uncontrolled …
Early outpatient treatment for Covid-19 with convalescent plasma
Background Polyclonal convalescent plasma may be obtained from donors who have
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in …
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in …
Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19: a randomized clinical trial
H Abdelhady, M Abdelrazik, Z Abdi, D Abdo, A Abdulle… - Jama, 2021 - jamanetwork.com
Importance The evidence for benefit of convalescent plasma for critically ill patients with
COVID-19 is inconclusive. Objective To determine whether convalescent plasma would …
COVID-19 is inconclusive. Objective To determine whether convalescent plasma would …
Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
Antibody-mediated neutralization of SARS-CoV-2
Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, PW Horby… - Medrxiv, 2021 - medrxiv.org
Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …